Anatumomab mafenatox

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Anatumomab mafenatox
Monoclonal antibody
Type Fab fragment
Source Mouse
Target TAG-72
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
  (verify)

Anatumomab mafenatox is a mouse monoclonal antibody studied for the treatment non-small cell lung cancer,[1] which acts as a tumor-targeted superantigen.[2]

It is a fusion protein of a human tumor-associated 5T4 antigen monoclonal IgG1 Fab fragment with an enterotoxin ('mafenatox') of Staphylococcus aureus.[3]

Development was abandoned in 2005.[4]

References[edit]

  1. ^ "Active Biotech". activebiotech.com. Retrieved 25 May 2016. 
  2. ^ Hedlund, Gunnar; Forsberg, Göran; Nederman, Thore; Sundstedt, Anette; Dahlberg, Leif; Tiensuu, Mikael; Nilsson, Mats (2013). "Tumor-Targeted Superantigens": 365–381. doi:10.1002/9781118354599.ch24. 
  3. ^ "Drug info" (PDF). World Health Organisation. Retrieved 25 May 2016. 
  4. ^ http://adisinsight.springer.com/drugs/800013422